White House aide nominated for FDA commissioner role

20 August 2026

US President Donald Trump has nominated Heidi Overton, deputy director of the White House Domestic Policy Council, as the next commissioner of the Food and Drug Administration (FDA), announcing the choice in a social media post on Wednesday.

Dr Overton is a physician who has worked on several of the administration's second-term health initiatives, including drug pricing agreements with manufacturers and an effort to accelerate development of psychedelic treatments. She trained in general surgery at Johns Hopkins and was a White House fellow during President Trump's first term.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical